Article
Nutrition & Dietetics
Somayyeh Asghari, Mahsa Rezaei, Maryam Rafraf, Mahdiyeh Taghizadeh, Mohammad Asghari-Jafarabadi, Maryam Ebadi
Summary: This study investigated the effects of a calorie-restricted diet on oxidative/anti-oxidative status in patients with nonalcoholic fatty liver disease (NAFLD) and the potential mediating role of fibroblast growth factor 21 (FGF-21). The results showed that the calorie-restricted diet had favorable effects on NAFLD but did not modify oxidative/anti-oxidative status in these patients.
Article
Cardiac & Cardiovascular Systems
William Tucker, Bradley Tucker, Kerry-Anne Rye, Kwok Leung Ong
Summary: Fibroblast growth factor 21 (FGF21) is a hormone involved in energy regulation and has been shown to protect against obesity and diabetes. However, its role in heart failure (HF) is not well understood. HF is a global health problem with a rising prevalence, especially in aging populations. The emergence of cardiac biomarkers has been of great interest in improving prediction, diagnosis, and prognosis of HF. Recent studies suggest that FGF21 may be a promising biomarker for HF, but there are conflicting findings in clinical literature. Further research is needed to understand the causal role of FGF21 in HF and its potential as a biomarker for prediction, diagnosis, and prognosis.
HEART FAILURE REVIEWS
(2023)
Review
Physiology
Xue Zhou, Yuefeng Zhang, Ning Wang
Summary: Chronic kidney disease is a progressive and incurable disease that can lead to various complications and it is crucial to prevent and treat it at an early stage. FGF21, as an important regulatory factor in cellular functions, may have a potential relationship with kidney diseases, but further studies are needed to explore its biological role in this context.
FRONTIERS IN PHYSIOLOGY
(2021)
Article
Endocrinology & Metabolism
Li-Hsin Chang, Chia-Huei Chu, Chin-Chou Huang, Liang-Yu Lin
Summary: This study found that FGF-21 levels were associated with an increased risk of renal events in Chinese patients with T2DM. FGF-21 may serve as a potential biomarker to predict renal outcomes in T2DM.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Ying Yu, Yingjie Shen, Siyi Zhang, Nan Wang, Lan Luo, Xinyi Zhu, Xiejun Xu, Weitao Cong, Litai Jin, Zhongxin Zhu
Summary: The study demonstrates that FGF21 can suppress inflammation induced by C. acnes through counteracting activation of TLR2, NF-κB, and MAPK signaling pathways and reducing the expression of inflammatory cytokines.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Clinical Neurology
Xiaowei Zheng, Zhengbao Zhu, Daoxia Guo, Chongke Zhong, Tan Xu, Yanbo Peng, Aili Wang, Hao Peng, Zhong Ju, Deqin Geng, Yonghong Zhang, Jiang He
Summary: Elevated plasma fibroblast growth factor 21 (FGF-21) levels were found to be associated with poor prognosis in patients with acute ischemic stroke, increasing the risk of death or major disability. Using FGF-21 as a prognostic marker may help evaluate the prognosis of stroke patients.
EUROPEAN JOURNAL OF NEUROLOGY
(2021)
Review
Immunology
Hayder M. Al-kuraishy, Ali I. Al-Gareeb, Hebatallah M. Saad, Gaber El-Saber Batiha
Summary: FGF21 is a hormone synthesized and released from the liver. In type 2 diabetes, FGF21 is released to overcome insulin resistance stimulated by inflammation. Metformin increases FGF21 expression and improves its sensitivity, thereby improving insulin sensitivity and glucose homeostasis.
INFLAMMOPHARMACOLOGY
(2023)
Review
Endocrinology & Metabolism
Maria Porflitt-Rodriguez, Valentina Guzman-Arriagada, Romina Sandoval-Valderrama, Charmaine S. Tam, Francisca Pavicic, Pamela Ehrenfeld, Sergio Martinez-Huenchullan
Summary: This article systematically reviewed the effects of aerobic exercise on FGF21 in overweight and obese individuals. It found that acute exercise tends to increase circulating levels of FGF21, while chronic exercise programs have the opposite effect and induce increases in FGF receptors and beta-klotho in adipose tissue, liver, and skeletal muscle.
METABOLISM-CLINICAL AND EXPERIMENTAL
(2022)
Article
Gastroenterology & Hepatology
Zhao-yan Liu, Yan Luo, Ai-ping Fang, Maierhaba Wusiman, Tong-tong He, Xiao-zhan Liu, Dinuerguli Yishake, Si Chen, Xiao-ting Lu, Yao-jun Zhang, Hui-lian Zhu
Summary: The study concluded that higher serum FGF21 levels were associated with worse survival in HCC patients, suggesting that serum FGF21 may be used as a novel metabolism-related prognostic biomarker for HCC.
LIVER INTERNATIONAL
(2022)
Review
Biochemistry & Molecular Biology
Yan Tang, Mei Zhang
Summary: FGF21 is primarily produced in the liver and adipose tissue and plays a crucial role in regulating energy metabolism of carbohydrates and lipids in the body. It has potential clinical value in treating metabolic disorders. However, the abuse and abnormal expression of FGF21 may be associated with bone abnormalities. The role of FGF21 in bone metabolism regulation and its mechanism are still not fully understood, but worthy of increasing attention.
BIOMEDICAL JOURNAL
(2023)
Review
Biochemistry & Molecular Biology
Hyunjoong Kim, Jihye Jung, Sungeon Park, Younglan Joo, Sangbong Lee, Jeongu Sim, Jinhyeong Choi, Hyun Lee, Gyujeong Hwang, Seungwon Lee
Summary: This systematic review synthesized and quantified the changes in fibroblast growth factor-21 (FGF-21) induced by exercise. Through searching and analysis of 10 studies with 376 participants, it was found that FGF-21 levels significantly increased after exercise compared to no exercise. The results suggest that chronic exercise leads to higher FGF-21 levels.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Pharmacology & Pharmacy
Qin-Ying She, Li-Juan Li, Ming-Hong Liu, Ru-Yu Tan, Yi-Wen Zhong, Jing-Fu Bao, Jie-Dong Xie
Summary: This study used bibliometric analysis to evaluate the state and future directions of FGF-21 research over the past 20 years. The results showed that the peripheral metabolic effects of FGF-21, FGF-21-based drug development, and translational research on metabolic diseases were the major topics of research. The emerging trends were the central metabolic effects of FGF-21 and the effects of FGF-21 on non-metabolic diseases.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Hua-Chun Weng, Xin-Yu Lu, Yu-Peng Xu, Yi-Hong Wang, Dan Wang, Yi-Ling Feng, Zhang Chi, Xiao-Qing Yan, Chao-Sheng Lu, Hong-Wei Wang
Summary: FGF21 has shown to reverse salt-sensitive hypertension-induced nephropathy by inhibiting inflammation and oxidative stress, suggesting it as a promising pharmacological strategy for treatment.
MOLECULAR MEDICINE
(2021)
Review
Endocrinology & Metabolism
Qin-Ying She, Jing-Fu Bao, Hui-Zhen Wang, Huixin Liang, Wentao Huang, Jing Wu, Yiwen Zhong, Hanxin Ling, Aiqing Li, Shu-Lan Qin
Summary: This article summarizes the important roles of fibroblast growth factor 21 in metabolic homeostasis and highlights its pharmacological potential in mitigating metabolic disorders. However, the current clinical trials have not achieved the desired results, raising questions about its clinical value.
METABOLISM-CLINICAL AND EXPERIMENTAL
(2022)
Review
Orthopedics
Hao Liu, Xia He, Xiao-Yan Deng, Jing-Lu Yan
Summary: This study systematically reviewed the relationship between FGF-21 levels and sarcopenia, as well as the related influential factors. The results showed that the sarcopenia group had significantly lower BMI and reduced grip strength compared to the non-sarcopenia group. However, there was no significant difference in serum FGF21 levels between the two groups, and FGF21 cannot be used as a biological or diagnostic marker for sarcopenia.
BMC MUSCULOSKELETAL DISORDERS
(2023)
